Kratom (Mitragyna speciosa): Friend or Foe?

Clicks: 397
ID: 88019
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #4 of 17 articles by views in The primary care companion for CNS disorders

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Increased use of the opioid-related plant kratom as an alternative treatment for opioid withdrawal symptoms has raised concerns regarding its potential for abuse and severe adverse effects. A review of the literature was performed to characterize kratom's pharmacology, clinical efficacy, and adverse effects to increase understanding and evaluate potential use as an alternative treatment for opioid dependence. Kratom use initiated as self-medication for an opioid use disorder or pain syndrome in the absence of effective alternatives is associated with a risk of kratom dependence, withdrawal, and life-threatening toxicity. The potential for a serious adverse reaction should discourage unregulated use of kratom products.
Reference Key
sethi2020kratomthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sethi, Roopa;Hoang, Nguyen;Ravishankar, Dheepthi Arakonam;McCracken, Megan;Manzardo, Ann M;
Journal The primary care companion for CNS disorders
Year 2020
DOI
10.4088/PCC.19nr02507
URL
Keywords
nlrp3 akt mtorc1 myocardial ischemia-reperfusion (mi/r) scutellarin (scu)

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.